Skip to main content

Table 4 Follow-up after catheter ablation

From: Outcome of catheter ablation of non-reentrant ventricular arrhythmias in patients with and without structural heart disease

 Total (n = 256)SHD (n = 102)No SHD (n = 154)p value (SHD vs. no SHD)
Duration of follow-up, months34.7 ± 15.136.6 ± 15.233.4 ± 15.00.101
Patients with repeat ablation of any VA, n (%)47 (18.4)23 (22.5)24 (15.6)0.189
Patients with repeat ablation of initial VA, n (%)40 (15.6)20 (19.6)20 (13.0)0.179
PVC burden at baseline, %17.0 ± 13.416.9 ± 13.817.1 ± 13.20.901
PVC burden at follow-up, %3.8 ± 7.85.5 ± 9.52.8 ± 6.40.005*
PVC count at baseline, n17,324 ± 14,91816,208 ± 14,56817,979 ± 15,1470.309
PVC count at follow-up, n3620 ± 73275154 ± 86172720 ± 63220.002*
LVEF at baseline, %56 ± 1049 ± 1160 ± 6< 0.001*
LVEF at follow-up, %56 ± 1050 ± 1260 ± 5< 0.001*
AAD at baseline, n (%)150 (59.0)80 (78.4)70 (45.5)< 0.001*
AAD at follow-up, n (%)142 (55.5)82 (80.4)60 (39.0)< 0.001*
Time to repeat ablation, months11.5 ± 11.311.3 ± 9.811.8 ± 12.40.892
  1. AAD antiarrhythmic drugs (class I–IV), ECG electrocardiogram, LVEF left ventricular ejection fraction, PVC premature ventricular contraction, SHD structural heart disease, VA ventricular arrhythmia
  2. Values are mean ± standard deviation or n (%). *p <0.05 was considered statistically significant. Patients with completed follow-up (n = 256 out of 266)